Rationale for use mefloquine for COVID-19 treatment
Open Access
- 28 October 2020
- journal article
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 4S,p. 103-105
- https://doi.org/10.37489/2588-0519-2020-s4-103-105
Abstract
Currently, the use of mefloquine in patients with COVID-19 does not have sufficient scientific justification and, given the unfavorable efficacy and safety profile, cannot be considered for routine use in clinical practice.Keywords
This publication has 3 references indexed in Scilit:
- In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19OMICS: A Journal of Integrative Biology, 2020
- Prediction of Severity of Drug-Drug Interactions Caused by Enzyme Inhibition and ActivationMolecules, 2019
- Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesisNature Microbiology, 2017